Corifollitropin alfa


Concise Prescribing Info
Indications/Uses
Ovarian stimulation regimens for assisted reproduction in infertility.
Dosage/Direction for Use
Adult : SC ≤36 yr ≤60 kg: 100 mcg. >60 kg: 150 mcg; >36 yr ≥50 kg: 150 mcg. Given as a single dose on stimulation day 1, followed by a GnRH antagonist started on stimulation day 5 or 6 depending on ovarian response.
Dosage Details
Subcutaneous
Ovarian stimulation regimens for assisted reproduction in infertility
Adult: Combination therapy w/ gonadotropin-releasing hormone (GnRH) antagonist: ≤36 yr ≤60 kg: 100 mcg. >60 kg: 150 mcg; >36 yr ≥50 kg: 150 mcg. Given as a single dose on stimulation day 1, followed by a GnRH antagonist started on stimulation day 5 or 6 depending on ovarian response.
Contraindications
Ovarian, breast, uterine, pituitary, hypothalamic tumours; abnormal vaginal bleeding, primary ovarian failure, enlarged ovaries, ovarian cyst, history of ovarian hyperstimulation syndrome (OHSS); previous controlled ovarian stimulation (COS) cycle yielding >30 follicles measuring ≥11 mm; >20 basal antral follicle count, uterine fibroid tumour, reproductive organ malformation, polycystic ovarian syndrome (PCOS). Pregnancy and lactation.
Special Precautions
Patient w/ risk factors for thromboembolic events (e.g. family history, severe obesity, thrombophilia); history of multiple infertility treatment; history of ovarian torsion, previous or current ovarian cysts, risk factor for high ovarian response. Renal impairment.
Adverse Reactions
Significant: Ovarian torsion, multiple pregnancies and births, ectopic pregnancies, congenital malformations, ovarian and other reproductive system neoplasms, thromboembolic events.
Nervous: Headache, dizziness, fatigue.
GI: Nausea.
Genitourinary: Pelvic discomfort/pain.
Endocrine: Breast tenderness.
Potentially Fatal: Severe OHSS.
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
MonitoringParameters
Assess infertility prior to treatment. Monitor for signs of OHSS in patients receiving 1st cycle of treatment.
Lab Interference
May cause false +ve HCG pregnancy test.
Action
Description: Corifollitropin alfa is a long acting modified recombinant FSH agonist. It initiates and sustains follicular growth for 1 wk. This is achieved by adding a carboxy-terminal peptide of β-subunit of HCG to the β-chain of human FSH.
Pharmacokinetics:
Absorption: Bioavailability: 58%. Time to peak plasma concentration: 44 hr.
Distribution: Distributed mainly to ovaries and kidneys. Volume of distribution: 9.2 L.
Excretion: Mainly via urine. Elimination half-life: 70 hr.
Storage
Store between 2-8°C. Do not freeze.
Any unused portions should be disposed of in accordance w/ local requirements.
ATC Classification
G03GA09 - corifollitropin alfa ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
References
Buckingham R (ed). Corifollitropin Alfa. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/09/2017.

Joint Formulary Committee. Corifollitropin Alfa. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/09/2017.

Disclaimer: This information is independently developed by MIMS based on Corifollitropin alfa from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in